A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: urban (3), residential (24), industrial (50)

InP-Bleomycin-Cisplatin-Etoposide (5 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 5 Day) In-Patient Regimen Regimen Germ Cell – InP-Bleomycin-Cisplatin-Etoposide (5 day BEP) I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Bleomycin-Cisplatin-Etoposide-5-day-BEP-Ver1.2.pdf

Bleomycin-Cisplatin-Etoposide (3 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 3 Day) Regimen Germ Cell – Bleomycin-Cisplatin-Etoposide (3 day BEP) Indication In patients 4
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/Bleomycin-Cisplatin-Etoposide-3-day-BEP-Ver1.2.pdf

Darolutamide

Description
Chemotherapy Protocol PROSTATE CANCER DAROLUTAMIDE Regimen • Prostate - Darolutamide Indication • Darolutamide is recommended where the; - patient has a
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Prostatecancer/Darolutamide.pdf

Pembrolizumab2mg/kg

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Afatinib Ver 1

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Regimen AFATINIB NSCLC - Afatinib Indication Treatment of locally advanced or me
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AfatinibVer1.pdf

Pembrolizumab_400mg (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (400mg) Regimen • Lung Cancer – Pembrolizumab (400mg) Indication The treatment of untreated
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (NSCLC)

Description
Regimen Chemotherapy Protocol LUNG CANCER Pembrolizumab (200mg) • Lung Cancer – Pembrolizumab (200mg) Indication The treatment of untr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab-200mg.pdf

Pembrolizumab 400mg (bladder)

Description
Chemotherapy Protocol BLADDER CANCER Pembrolizumab (400mg) Regimen • Bladder – Pembrolizumab (400mg) Indication • Pembrolizumab is indicated f
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-400mg.pdf

Pembrolizumab 200mg (bladder)

Description
Chemotherapy Protocol BLADDER CANCER Pembrolizumab (200mg) Regimen • Bladder – Pembrolizumab (200mg) Indication • Pembrolizumab is indicated for locally advan
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Pembrolizumab-200mg.pdf

Rituximab (weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (weekly) Regimen Lymphoma – Rituximab (weekly) Indication CD20 positive indolent non Hodgkin’s lymphoma. Toxicity Drug R
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-weekly.pdf
421 to 430 of 1000
Previous … 41 42 43 44 45 … Next